OBJECTIVES: To review the evidence for efficacy and metabolic effects of atypical antipsychotics (AAPs), and to propose a metabolic monitoring protocol for AAP use in children and adolescents. METHODS: A PubMed search was performed to obtain all studies related to efficacy, metabolic side-effects, and monitoring in those less than 18 years of age. RESULTS: There are no approved indications for AAP use in children and adolescents in Canada. Based on US Food and Drug Administration approvals and a review of randomized controlled trials, we identified 7 indications for AAP use that target specific symptoms in youth including schizophrenia, bipolar I disorder, autism, pervasive developmental disorder, disruptive behaviour disorders (including conduct disorder and ADHD), developmental disabilities and Tourette Syndrome. A wide range of metabolic effects including weight gain, increased waist circumference, dysglycemia, dyslipidemia, hypertension, elevated hepatic transaminases and prolactin levels have been reported. We have developed a proposal for metabolic monitoring that includes anthropometric measurements and laboratory testing at baseline and appropriate intervals thereafter. CONCLUSION: There is an urgent need for national clinical practice guidelines that provide, not only appropriate treatment algorithms for AAP-use based on evidence, but also address metabolic monitoring and subsequent management of complications in this vulnerable population.
OBJECTIVES: To review the evidence for efficacy and metabolic effects of atypical antipsychotics (AAPs), and to propose a metabolic monitoring protocol for AAP use in children and adolescents. METHODS: A PubMed search was performed to obtain all studies related to efficacy, metabolic side-effects, and monitoring in those less than 18 years of age. RESULTS: There are no approved indications for AAP use in children and adolescents in Canada. Based on US Food and Drug Administration approvals and a review of randomized controlled trials, we identified 7 indications for AAP use that target specific symptoms in youth including schizophrenia, bipolar I disorder, autism, pervasive developmental disorder, disruptive behaviour disorders (including conduct disorder and ADHD), developmental disabilities and Tourette Syndrome. A wide range of metabolic effects including weight gain, increased waist circumference, dysglycemia, dyslipidemia, hypertension, elevated hepatic transaminases and prolactin levels have been reported. We have developed a proposal for metabolic monitoring that includes anthropometric measurements and laboratory testing at baseline and appropriate intervals thereafter. CONCLUSION: There is an urgent need for national clinical practice guidelines that provide, not only appropriate treatment algorithms for AAP-use based on evidence, but also address metabolic monitoring and subsequent management of complications in this vulnerable population.
Authors: Margaret Weiss; Constadina Panagiotopoulos; Lauren Giles; Christopher Gibbins; Boris Kuzeljevic; Jana Davidson; Rebecca Harrison Journal: J Child Adolesc Psychopharmacol Date: 2009-10 Impact factor: 2.576
Authors: Araba F Chintoh; Steve W Mann; Loretta Lam; Carol Lam; Tony A Cohn; Paul J Fletcher; Jose N Nobrega; Adria Giacca; Gary Remington Journal: J Clin Psychopharmacol Date: 2008-10 Impact factor: 3.153
Authors: Ronald N Marcus; Randall Owen; Lisa Kamen; George Manos; Robert D McQuade; William H Carson; Michael G Aman Journal: J Am Acad Child Adolesc Psychiatry Date: 2009-11 Impact factor: 8.829
Authors: Nick C Patel; Monica Hariparsad; Mary Matias-Akthar; Michael T Sorter; Drew H Barzman; John A Morrison; Kevin E Stanford; Stephen M Strakowski; Melissa P DelBello Journal: J Child Adolesc Psychopharmacol Date: 2007-06 Impact factor: 2.576
Authors: L J S Schweren; C A Hartman; M P Zwiers; D J Heslenfeld; D van der Meer; B Franke; J Oosterlaan; J K Buitelaar; P J Hoekstra Journal: Eur Child Adolesc Psychiatry Date: 2014-11-14 Impact factor: 4.785